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Pediatric oncology, notably childhood acute lymphoblastic leukemia (ALL), is currently 
one of the health-leading concerns worldwide and a biomedical priority. Decreasing 
overall leukemia mortality in children requires a comprehensive understanding of its 
pathobiology. It is becoming clear that malignant cell-to-niche intercommunication and 
microenvironmental signals that control early cell fate decisions are critical for tumor 
progression. We show here that the mesenchymal stromal cell component of ALL bone 
marrow (BM) differ from its normal counterpart in a number of functional properties and 
may have a key role during leukemic development. A decreased proliferation potential, 
contrasting with the strong ability of producing pro-inflammatory cytokines and an aber-
rantly loss of CXCL12 and SCF, suggest that leukemic lymphoid niches in ALL BM are 
unique and may exclude normal hematopoiesis. Cell competence ex vivo assays within 
tridimensional coculture structures indicated a growth advantage of leukemic precursor 
cells and their niche remodeling ability by CXCL12 reduction, resulting in leukemic cell 
progression at the expense of normal niche-associated lymphopoiesis.
Keywords: acute lymphoblastic leukemia, tumor microenvironment, cXcl12, leukemic niches, pro-inflammatory 
bone marrow
inTrODUcTiOn
The increasing evidence of the tumor microenvironment role in carcinogenesis has substantially 
modified the perspective of cancer pathobiology, favoring a more integrative view that considers 
the convergence of cellular genetics and an abnormal microenvironment as crucial elements for 
the development and maintenance of the disease (1). Notably, in concordance with most types 
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of cancer, induced chronic inflammation and editing of the 
microenvironment by tumoral cells have been reported in some 
hematological malignancies, including acute lymphoblastic 
leukemia (ALL) (2–5).
Acute lymphoblastic leukemia, characterized by a mul-
ticlonal uncontrolled production of lymphohematopoietic 
precursors, represents the most frequent childhood malignancy 
worldwide, showing a higher incidence in the Hispanic popula-
tion and specifically, an increased ratio of high-risk patients in 
Mexico (6–8). Despite the notable progression in the disease 
management (9,  10), the emergence of mixed-lineage leuke-
mias, chemoresistance, and minimal residual disease decreases 
the probabilities for therapy success and determines relapse 
in more than 20% of the treated patients. As observed for the 
normal hematopoietic progenitors, neither premalignant cells 
nor leukemic blasts work as independent and autonomous 
entities, but they are rather surrounded in all dimensions by 
bone marrow (BM) niche components that provide regulatory 
cues essential for their cell fate decisions such as proliferation 
and survival (11–14). The hematopoietic microenvironment 
under homeostatic conditions is a highly organized complex 
and dynamic network of cells [including mesenchymal stro-
mal cells (MSC), osteoblasts, adipocytes, endothelial cells, 
innate immune cells, etc.] and their natural products such as 
cytokines, chemokines, and extracellular matrix forming a sup-
portive scaffold for hematopoiesis (4, 5). Based on their major 
non-hematopoietic cellular components, at least three distinct 
BM hematopoietic stem cell niches have been identified: the 
endosteal niche, shaped by osteoblasts lining the bone surface at 
the endosteum, the vascular niche formed with endothelial cells, 
and the perisinusoidal reticular niche built by a heterogeneous 
population of networking stromal cells with long processes and 
abundant expression of CXCL12 and leptin receptor (4, 15–17). 
Remarkably, CXCL12-expressing osteoblasts and perivascular 
stromal cells are critical for the earliest stages of the lymphoid 
program (18, 19) and may additionally provide FLT3L, SCF, and 
IL-7 that are essential factors for development of B-lymphoid 
progenitor and precursor cells. Depletion of CXCL12 in the 
stromal cells that constitute the lymphoid niche critically dimin-
ishes commitment and differentiation of B cell progenitors (18). 
An overlap existing between CXCL12-SCF- and IL-7-producing 
cells has been recently suggested (20, 21).
In the initial stage of leukemogenesis, normal and malignant 
populations apparently share BM niches. However, it is becoming 
clear that progressive changes in both, cell composition and func-
tion of the microenvironment may govern abnormal progenitor 
cell activity and drive to establishment of exclusive structures 
suitable for leukemic cell proliferation but incompatible for sus-
taining normal hematopoiesis, that ultimately lead to disease (4, 
22–26). Previous studies in mice models and leukemia patients 
revealed that some of the BM microenvironmental alterations 
include an increased concentration of SCF and a decreased 
production of CXCL12 (2, 24, 27). Furthermore, remodeling of 
BM niche to favor tumor progression over normal cells (a niche-
dependent with niche alteration mechanism) has been recently 
suggested by elegant experimental chronic myeloid leukemia 
models where leukemic cells decreased expression of CXCL12 
concomitant to increased G-CSF production, impairing normal 
hematopoiesis and facilitating leukemia growth (22, 28). Of note, 
a similar scenario has been documented for xenografted ALL 
precursor cells that disrupt the normal niches by downregula-
tion of CXCL12 and further exclusion of normal HSC from their 
natural niche (24).
Accordingly, previous work in our lab suggests an impor-
tant damage in the frequency and function of hematopoietic 
stem and progenitor cells (HSPC) in the BM of ALL patients 
accompanied by an abnormal and pro-inflammatory secre-
tion profile (e.g., increased secretion of IL-1β and TNFα) (29, 
30). In order to address the molecular pathways involved in 
hematopoietic and microenvironmental alterations that may 
favor disease progression, we recently constructed a Boolean 
model, which demonstrates that constitutive activation of 
NF-κB in the hematopoietic molecular network was sufficient 
to establish a positive feedback loop that maintain the con-
stitutive secretion of pro-inflammatory cytokines (e.g., IL-1β 
and G-CSF) and induce the disruption of the CXCR4/CXCL12 
axis, which is crucial for the maintenance of the hematopoietic 
cells in their regulatory niche. Interestingly, this constitutive 
activation also induces the upregulation of the alternative 
CXCL12 receptors that may activate additional mechanisms 
to make front to pro-inflammatory insults (31). Thus, both, 
experimental and theoretical observations strongly indicate 
a fundamental role of MSC and CXCL12 expression levels in 
leukemia progression.
Our findings now suggest that the expression of CXCL12 in 
BM lymphoid niches under pro-inflammatory settings is criti-
cally reduced in ALL, allowing the malignant cell dominance over 
normal differentiation.
MaTerials anD MeThODs
isolation of normal and leukemic cells 
from BM
Bone marrow specimens, collected according to international 
and institutional guidelines, were obtained through BM 
aspiration from 26 pediatric patients referred to the “IMIEM” 
Children’s Hospital (Toluca, Mexico) and to the “Moctezuma” 
Children’s Hospital (Mexico City, Mexico) and diagnosed 
with ALL, before any treatment (Table S1 in Supplementary 
Material). Control BM specimens were obtained from six 
healthy children undergoing minor orthopedic surgery. 
Mononuclear cells (MNC) were obtained by Ficoll-Paque (GE 
Healthcare) density gradient centrifugation and then enriched 
in the CD34+ fraction using the human CD34 MicroBead Kit 
UltraPure human (MiltenyiBiotec) according to the manufac-
turer’s instructions. Cell purity and yield were measured by 
flow cytometry using a BD FASCanto II. All procedures were 
approved by the Ethics, Research, and Biosafety Committees 
at the participant hospitals and by the National Committee of 
Scientific Research at the Mexican Institute for Social Security 
(CIEICE-007-01-13, R-2012-3602-29, and R-2015-785-120). 
All the samples were collected after written informed consent 
from the parents.
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isolation and expansion of BM Msc
Mononuclear cells (2–4 ×  106) from normal or leukemic BM 
were placed in culture with low glucose Dulbecco’s modified 
Eagle’s medium (DMEM, Gibco) supplemented with 10% 
fetal bovine serum (FBS, Gibco) and 100  U/ml of penicillin/
streptomycin (Gibco). MSC were then isolated by their plastic 
adherence properties according to the International Society for 
Cellular Therapy (23). Upon confluence, cell monolayers were 
trypsinized and reseeded for their expansion and biological 
characterization for at least one more week. All experiments were 
performed with harvested cells from the third or fourth passage. 
Immunophenotype of MSC was confirmed by flow cytometry as 
CD45−CD34−HLA-DR−CD90+CD73+CD105+.
Multi-lineage Differentiation  
capacity of Msc
To evaluate the chondrogenic differentiation potential of normal 
and ALL-MSC, they were cultured with chondrogenic medium 
[DMEM-alpha glucose, supplemented with 0.1µM dexametha-
sone, 50 µg/ml ascorbic acid, 110 µg/ml sodium pyruvate, 40 µg/
ml prolin, 10  ng/ml TGF-β1, 50  mg/ml ITS+ premix (Becton 
Dickinson), 6.25 µg/ml insulin, 6.25 µg/ml transferrin, 6.25 ng/
ml selenic acid, 1.25 mg/ml bovine serum albumin, and 5.35 mg/
ml linoleic acid] followed by Alcian blue staining after 14 days. 
For adipogenic differentiation, MSC were grown in medium sup-
plemented with 0.5mM isobutil-metilxantin, 1µM dexametasone, 
10µM insulin, and 200µM indomethacin, before red oil staining. 
Osteogenic differentiation was investigated using low glucose 
DMEM medium supplemented with 15% of osteogenic supple-
ment, 10−7M dexamethasone, and 0.2  mM ascorbic acid. Cells 
were grown during 3 weeks and then stained with von Kossa dye.
colony-Forming Units-Fibroblast  
(cFU-F) assay
Mesenchymal stromal cells’ progenitor frequencies were recorded 
by fibroblast colony formation assay. Crescent numbers of MNC 
were plated in DMEM supplemented with 10% of FBS and 14 days 
later Wright–Giemsa staining was performed to determine the 
CFU-F content.
Msc Proliferation assay
A carboxifluorescein (CFSE) dilution assay was conducted using 
10mM CFSE per 5 × 105 MSC and dye dilution evaluated by flow 
cytometry at 24 and 48 h.
rT-Pcr analyses for Msc Differentiation
Transcription of differentiation-related genes was evaluated 
by RT-PCR using the following primers: PPARγ2, Runx2, 
Sox9, CXCL12, HIF-1α, and IL7, with the 18s ribosomal RNA 
as housekeeping control. cDNAs were subject of amplifica-
tion by RT-PCR (95°C initial denaturalization for 5  min, 35 
amplification cycles of 5  s at 95°C, and aligning temperature 
in function of every single gene during 30  s and 72°C during 
10  min) in a thermal cycler T100 ™BIORAD. AlphaView 
software (FluorChem System) was used for analysis. Primer 
sequences: Runx2: F: 5′-CACCATGTCAGCAAAACTTCTT-3′; 
R: 5′-TCACGTCGCTCATTTTGC-3′. Sox9: F: 5′-GTACCC 
GCACTTGCACAAC-3′; R: 5′-TCGCTCTCGTTCAGAAGT 
CTC-3′. PPARG2: F: 5′-TCCATGCTGTTATGGGTGAA-3′; R: 
5′-TGTGTCAACCATGGTCATTTC-3′. CXCL12: F: 5′-CCAAA 
CTGTGCCCTTCAGAT-3′; R: 5′-CTTTAGCTTCGGGTCAAT 
GC-3′. 18s: F: 5′-AAATCCAGCGCAGTACAAGATCCCA-3′; R: 
5′-TTTCTTCTTGGACACACCCACGGT-3′.
lymphoid Differentiation  
coculture system
Around 1,000 lymphoid progenitors were seeded (input value) 
in alpha-MEM 10% FBS supplemented with 100 ng/ml rhSCF, 
100  ng/ml rhFlt3-L, 20  ng/ml rhIL-7, and 10  ng/ml rhIL-15. 
Cocultures were maintained during 3–6 weeks, and B precursor 
cells production was evaluated by multiparametric flow cytom-
etry (FACSCalibur, BD). Results were recorded as yield per input 
(absolute number of B cell precursors that are produced per each 
initial progenitor).
Flow cytometry analyses  
of cell Populations
Hematopoietic Cells
CD34+ cells from normal bone marrow (NBM) and ALL were 
enriched using the Human CD34 Progenitor Cell Isolation Kit 
(Miltenyi Biotec) according to the manufacturer’s instructions. 
After staining with PE-conjugated anti-lineage markers (CD3, 
CD8, TCR, CD56, CD14, CD11b, CD20, CD19, and CD235a) 
and anti-CD34-APC, primitive cell populations were highly puri-
fied by multicolor flow cytometry using a FACSAria sorter (BD 
Biosciences). HSPC were separated as Lin-CD34+. Upon harvest-
ing from culture, anti-CD56 and anti-CD19 antibodies were used 
to evaluate cell production in lymphoid lineage conditions. Pro-B 
blast population was identified as CD34+CD19+, while Pre-B cells 
as CD34−CD19+.
Mesenchymal Stromal Cells
Immunophenotyping was conducted by surface staining of MSC 
with 1:100 dilution antibodies, while intracellular staining was 
performed by incubating primary CXCL12 and HIF-1α antibod-
ies (1:100 dilution) during 2 h at 4°C in the dark upon cell fixation 
and permeabilization using Cytofix/Cytoperm (BD Biosciences) 
solution, according to the manufacturer’s instructions. After cell 
washing, the appropriate secondary antibody (1:1,000 dilution) 
was incubated for 1 h at 4°C in the dark. Cells were washed, and 
the pellets resuspended prior to flow cytometry analysis. Analysis 
of flow cytometry data was performed using the FlowJo 7.6.1 
software (TreeStar Inc., Ashland, OR, USA).
antibodies
Most primary and secondary antibodies came from Abcam: 
mouse monoclonal CXCL12 (MM0211-9N26), rabbit recom-
binant monoclonal SCF (EP665Y), rabbit polyclonal HIF-1α 
(AB103063), or mouse monoclonal connexin-43 (Cx-43) (4E6.2). 
Goat Anti-Mouse Alexa Fluor® 488 (IgG H&L) (ab150113), 
Goat Anti-Rabbit Alexa Fluor® 405 (IgG H&L) (ab175652), and 
Donkey Anti-Mouse Alexa Fluor® 405 (IgG H&L) (ab175658). 
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Rabbit Anti-Human phospho-NF-kB p65 (ser536) (93H1) came 
from cell signaling. Source for immunophenotyping antibod-
ies: CD34-APC (Clone 581, BioLegend), CD19-FITC (Clone 
HIB19, BioLegend), CD45-PECy5 (Clone HI30, BioLegend), 
HLA-DR-PE (clone L243, BioLegend), CD90-APC (5E10, BD), 
CD73-PE (AD2, BD), and CD105-FITC (266, BD).
cytokines Detection
Supernatants were removed from normal and ALL-MSC cultures 
and the secreted factors quantified by multiplex cytokine detec-
tion assay (Milliplex Map, Millipore) according to the manufac-
turer’s instructions.
induction of hypoxic conditions
Mesenchymal stromal cells were treated with 100µM cobalt chlo-
ride II (CoCl2) during 24 h. Cytoplasmic stabilization of HIF-1α 
was measured by flow cytometry and its nuclear translocation by 
indirect immunofluorescence microscopy.
hematopoietic Proliferation by BrdU 
incorporation assay
Mesenchymal stromal cells–hematopoietic cell cocultures were 
supplemented with BrdU during 24 h and leukemic cells harvested, 
fixed, and permeabilized. DNAse treatment was performed for 
1 h at 37°C before cell incubation with anti-BrdU. Proliferation 
rates were analyzed by multiparametric flow cytometry.
indirect immunofluorescence Microscopy
Mesenchymal stromal cells were fixed with paraformaldehyde 
4% and permeabilized with PBS–Triton 0.01%. Fc receptors were 
blocked with 3% PBS–FBS, and cells were incubated overnight 
with anti-CXCL12, anti-SCF, anti-HIF-1α, anti-IL-7, anti-Cx-43, 
or anti-phospho-p65 monoclonal antibodies. AlexaFluor®488 
and AlexaFluor®405 conjugated antibodies were further added. 
Nuclei were stained with propide iodide before cell preparations 
were analyzed in a confocal microscope (NIKON). Images were 
analyzed using the ImageJ 1.51h software (Wayne Rasband, NIH, 
USA).
Tridimensional (3D) coculture system
Mesenchymal stromal cells were induced to form spheroids in 
non-adherent wells and leukemic precursor cells cocultured 
with each spheroid. Normal or leukemic cells were labeled with 
fluorescent dyes CellTraceViolet® or CellTrace Far Red® (Life 
Technologies) to distinguish each other by confocal microscopy 
throughout competence assays. Immunophenotype of leukemic 
cells were performed by flow cytometry after spheroid enzymatic 
digestion. CXCL12 expression was concomitantly evaluated by 
confocal microscopy. Briefly, spheroids were washed several times 
with PBS followed by fixing and permeabilization for 30  min. 
Spheroids were incubated with antibodies as described before.
statistics
Prism V3.02 (GraphPad) software was used to perform statisti-
cal data analysis. Yield per input results were showed as media 
values  ±  SD. Differences within groups were established by 
non-parametric test Mann–Whitney, considering significant 
probability values <0.05. For three or more groups, the Kruskal–
Wallis test has been applied. Comparative analyses are reported 
as Mean ± SEM.
resUlTs
Functional alterations in Msc set Up a 
Pro-inflammatory Microenvironment in 
all
Bone marrow MSC from childhood ALL patients were char-
acterized according to their morphological, phenotypical, and 
functional properties established as the minimal criteria by the 
International Society for Cellular Therapy (32). No differences 
in morphological aspects between cells from both sources were 
apparent. However, ALL-MSC showed intercellular disorganiza-
tion when monolayer structures were observed (Figure  1A). 
Remarkably, although CFU-F capacity and cell proliferation 
were reduced (Figures  1B,C), increasing proliferation activity 
was recorded when 7-day cultures were performed, suggesting 
that once the ALL primary MSC are adapted to in vitro culture 
conditions, autocrine growth factors may induce their high 
extent proliferation. Nevertheless, simple population dynamics 
assays by cell counting suggest ALL-MSC have no ability to 
reach normal rates (Figure S1 in Supplementary Material). In 
contrast, neither their differentiation potential to chondrogenic, 
adipogenic, and osteogenic lineages nor their phenotypes were 
truly compromised (Figures 1D,E). As known, although specific 
MSC markers are still under investigation, currently the most 
accepted phenotype is CD34−CD45−CD14/CD11−CD90+CD73+ 
CD105+ with variable expression of MHC II, CD29 (integrin 
β1), CD49b (integrin α2), CD44 (HCAM), CD54 (ICAM-1), 
CD58 (LFA-3), and CD166 (ALCAM). Here, our data indicate 
a correspondence in the phenotype of the MSC from ALL and 
NBM, showing minor differences in expression of HLA-ABC, 
CD13, CD73, CD140b, CD44, CD54, CD49b, and CD166, which 
may relate to potential abnormalities in the capacity of cell–cell 
intercommunication with leukemic precursors within the BM. 
Interestingly, as previously reported for angiogenic-stimulated 
abnormal MSC in hematological malignancies (33), CD90 was 
reduced in a subpopulation of ALL (Figure  1E; Figure S1 in 
Supplementary Material). Whether this molecule may discrimi-
nate more primitive stages of mesenchymal linage, as it does in the 
hematopoietic system, remains elusive. Differentiation gene tran-
scripts, including Runx2 (osteogenesis), Sox9 (chondrogenesis), 
and PPARG2 (adipogenesis) revealed a substantial reduction in 
Sox9 expression by ALL cells, suggesting altered lymphopoiesis 
associated to defects in osteochondrogenesis (Figure  1F) as 
reported (34). Despite the fact that PPARG2 expression was not 
obviously altered, a number of ALL BM samples displayed aug-
mented ability to differentiate toward adipocytes (Figure 1D).
Notably, the hematopoietic support capability of MSC 
from ALL BM was increased when compared to their normal 
counterparts (Figure 2A), though it is uncertain the normal or 
leukemic origins of such supported cells. When normal primitive 
FigUre 1 | Biological characterization of mesenchymal stromal cells (Msc) derived from bone marrow of all patients. MSC were evaluated according 
to morphology (a), colony-forming unit-fibroblast capacity (B), proliferation rates by carboxifluorescein dilution assay (c), multiple differentiation potential (NNBM = 5, 
NALL = 7) (D), minimal criteria immunophenotype (NNBM = 5, NALL = 7) (e), and differentiation genes expression (NNBM = 4, NALL = 5) (F). NBM, normal bone marrow; 
ALL, acute lymphoblastic leukemia.
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hematopoietic cells are placed onto ALL-MSC monolayers to 
support cell differentiation, the production of CD19+ B cells and 
CD56+ NK cells is critically impaired (evaluated as cell frequen-
cies and as yield per input progenitor). In contrast, near 30 and 
15% of the produced cells are CD19+ B-lineage or CD56+ NK 
cells, respectively, in normal to normal conditions (Figure S2 
in Supplementary Material). Together, the data may strengthen 
the notion that abnormal MSC from ALL BM constitute special 
niches convenient for leukemic cell proliferation and/or differen-
tiation but unable to sustain normal hematopoietic development 
(Figure S3 in Supplementary Material). Moreover, we extended 
these studies to explore the ALL-MSC ability of intercommu-
nicating to HSPC by evaluating the display of the major adhe-
sion VLA-4/VCAM-1 axis and found a substantial reduction 
of VLA-4 expression by ALL hematopoietic MNC, as well as 
decreased VCAM-1 expression by ALL-MSC. Thus, suboptimal 
adhesion and interplay between hematopoietic and mesenchymal 
components of the ALL BM may contribute to malignant cell 
maintenance at the expense of normal hematopoiesis (Figure S2 
in Supplementary Material).
At least 16 soluble factors relevant to lymphoid development 
were aberrantly secreted, as supernatant contents indicated high 
levels of pro-inflammatory cytokines IL-1α, IL-6, IL-12p70, and 
TNFα, as well as interferon type I and type II and early growth 
factors like Flt3, G-CSF, and IL-7 (Figure  2B). Remarkably, 
CXCL12 (stromal derived factor-1) and SCF (stem cell factor), 
two components of the hematopoietic microenvironment and 
main regulators of stem cell maintenance that have shown to be 
key players in the early lymphopoiesis pathway, were critically 
reduced. Accordingly, ALL-MSC-conditioned medium contained 
high amounts of G-CSF, which has shown the ability of mobiliz-
ing hematopoietic cells from BM through a CXCL12/CXCR4 axis 
breaking mechanism. The observed pro-inflammatory profile 
was supported by the nuclear NF-κB translocation in ALL-MSC 
(Figure  2C). Our findings suggest a pro-inflammatory micro-
environment contributed by activated MSC that may impact 
normal and leukemic developmental dynamics.
loss of cXcl12 Marks the leukemic 
niche within the BM
A crucial regulatory axis of the cross talk between lymphoid 
progenitors and the hematopoietic microenvironment is 
CXCL12/CXCR4. MSC producing high amounts of CXCL12 
and SCF constitute the primary niche for B-lymphoid pro-
genitor cells (20). Concurring with our previous supernatants 
FigUre 2 | acute lymphoblastic leukemia (all)-mesenchymal stromal cells (Msc) contribute to leukemic cell maintenance by creating a pro-
inflammatory microenvironment. Hematopoietic stem and progenitor cells (HSPC) from ALL bone marrow were cocultured on normal bone marrow (NBM)-MSC 
or ALL-MSC monolayers in lymphoid conditions during 4 weeks before flow cytometry analysis of the newly produced cells, and the B cell yield per input were 
recorded (NNBM = 5, NALL = 7) (a). Cytokines, chemokines, and growth factors production by NBM and ALL-MSC were evaluated after collection of 24-h 
supernatants. Data are normalized to NBM-MSC secretion (B) (NNBM = 5, NALL = 13). Phosphorylated p65 (NF-κB) was evaluated by immunofluorescence 
microscopy (NNBM = 3, NALL = 4) [(c), left panel] and flow cytometry [(c), left panel] of MSC (NNBM = 3, NALL = 5). Normalized nuclear fluorescence intensity and mean 
fluorescence intensity (MFI) from flow cytometry are shown.
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observation, confocal microscopy revealed the per-cell-basis 
reduced production of both factors (Figures 3A–D). In contrast, 
IL-7 lymphoid niche appears unaltered in ALL (Figure 3E). To 
explore the biological mechanism associated to CXCL12 loss, 
we investigated the gene transcription extent and found it 
heterogeneously impaired among patient samples (Figure 4A). 
In addition, the intercommunicating stromal cell Gap-junction 
molecule, Cx-43, which drives secretion of CXCL12 appeared 
frankly downregulated in ALL-derived MSC (Figure  4B). 
As it is believed that in BM, MSC maintain hematopoietic 
cells attached to them in a semi-quiescence state through the 
dynamic production of CXCL12, lack of Cx-43 impacting the 
release of CXCL12 (35) may have important implications in 
architecture and function of BM niches. Moreover, homing to 
the endosteal niche might relate to Cx-43, due to its participa-
tion in the bidirectional traffic from BM to the periphery and 
vice versa during ALL (36).
HIF-1α is a major transcriptional regulator of CXCL12 (37). 
Here, a critical reduction of its expression with a cytoplasmic 
localization instead of the typical nuclear translocation seen in 
their normal counterpart was recorded in ALL-MSC (Figure 5A). 
Furthermore, experimental hypoxia was not able to increase 
FigUre 3 | abnormal cXcl12 and scF production by mesenchymal B-lymphoid niche in acute lymphoblastic leukemia (all). CXCL12 (a–c), SCF 
(B,D,e), and IL-7 (e) production was evaluated by immunofluorescence microscopy and flow cytometry in mesenchymal stromal cells from normal (NBM) and ALL 
bone marrow (NNBM = 6, NALL = 12). CTV, cell trace violet.
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HIF-1α expression to normal levels. Chemical imitation of 
hypoxia by Chloride Cobalt (CoCl2) has been reported to create 
a hypoxic-like condition by disturbing the constant proteasomal 
degradation of HIF-1α and allowing its cytoplasmic accumulation 
and further nuclear translocation even during normoxic settings. 
Although expression of CXCL12 showed a slight boost, the end 
balance was never as high as from NBM (Figure 5B; Figure S4 in 
Supplementary Material).
Thus, in ALL, the CXCL12-dependent lymphoid niche might 
be intrinsically altered due at least to an impaired transcriptional 
regulation by HIF-1α and to an abnormal functional activity of 
Cx-43.
FigUre 4 | Transcriptional and post-translational downregulation of cXcl12 in all. CXCL12 mRNA expression was determined by RT-PCR in normal and 
ALL mesenchymal stromal cells (MSC) and their normalized gene expression tabulated (NNBM = 4, NALL = 6) (a). The gap-junction connexin-43 display by ALL-MSC 
and their normal counterpart was also analyzed by immunofluorescence microscopy and flow cytometry (B). NBM, normal bone marrow; ALL, acute lymphoblastic 
leukemia; MFI, mean fluorescence intensity.
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To investigate the biological relevance of loss of CXCL12 in 
leukemic progression, we conducted an in vitro cell proliferation 
assay by incorporation of BrdU under distinct CXCL12 scenarios. 
Primary leukemic cells were treated either with CoCl2 to increase 
CXCL12 expression or with carbenoxolone (CBX), a Cx-43 inhibi-
tor, to indirectly reduce CXCL12, and their proliferative status 
was analyzed (Figure  5C). Of interest, malignant proliferation 
extent was inversely proportional to CXCL12 expression in MSC. 
Cell treatment with CBX did not increase the proliferation of ALL 
cells over the initial mock settings, suggesting, as expected, that 
CXCL12 regulation may result from multiple addition elements. 
Since the role of CXCL12 in early lymphopoiesis has been vastly 
studied (18, 19), our findings suggest that CXCL12 lymphoid 
niche may have an additional function in normality by limiting 
proliferation of malignant precursor cells.
The cXcl12+ lymphoid niche is 
remodeled by leukemia Precursor cells, 
Favoring Tumor Progression at the 
expense of normal lymphopoiesis
Because in vitro maintenance of primary ALL cells in conven-
tional culture conditions and the 3D in vivo BM structure is criti-
cal to generate specialized hematopoietic niches, we explored the 
possibility of improving the microenvironmental conditions and 
increasing yield per input values by mimicking the structural 
BM properties through 3D cocultures in stromal spheroids. We 
have learned from this novel system that primitive normal and 
ALL CD34+ cells get the ability of colonizing them with high 
efficiency (Figures  6A–C) (Balandran et  al., manuscript in 
preparation).
Population dynamics was studied by a competence assay 
between purified CD34+ cell populations from ALL BM or healthy 
donors mobilized peripheral blood that were previously stained 
with red and blue commercial fluorescent dyes, respectively.
As expected, CXCL12 was induced in 3D cultures, possibly 
due to reconnection of MSC and the putative hypoxia condition 
within the system (Figure 6D). Notably, leukemic MSC were less 
colonized by normal progenitors compared to the NBM coun-
terparts at the first 24 h (Figure 6E). However, 120 h later, the 
normal niches were colonized by leukemic cells simultaneously 
to an apparent decrease of CXCL12 and displacement of normal 
progenitors (Figure 6F; Figure S5 in Supplementary Material).
DiscUssiOn
Tumor cells coexist with their normal counterparts in the same 
microenvironment. During cancer progression, they both 
contend for the niche and conditioned it for the sake of tumor 
benefit (38–40), as has been documented for myeloid leukemias 
(41) or in murine models (24). CXCL12 is an essential chemokine 
showing constitutive expression by BM cells that directly impacts 
retention, quiescence, and proliferation of hematopoietic stem 
cells and B-cell progenitors (42). Accordingly, CXCL12 knockout 
mouse prenatally die due the lacking of B lymphopoiesis and 
myelopoiesis in the BM (43), while initiating-leukemia cells 
express CXCR4 (44, 45) and respond to CXCL12 by delaying 
apoptosis processes (46).
The cell–cell intercommunication as key factor for tumor 
progression has became a research priority, and increasing 
evidence of leukemic blasts supported by Nestin+ MSC indicates 
their ability for long-term maintenance at the disease onset 
FigUre 5 | The cXcl12 mesenchymal niche disruption is associated to an abnormal hiF-1α regulation. HIF-1α and CXCL12 displayed by mesenchymal 
stromal cells (MSC) from normal or acute lymphoblastic leukemia (ALL) bone marrow were evaluated by immunofluorescence microscopy and flow cytometry upon 
standard cultures [(a), left panel] or hypoxic-like conditions promoted by CoCl2 treatment for 2 h [(B), left panel]. HIF-1α increase was monitored by flow cytometry 
[(a,B), middle panels]. Mean fluorescence intensity values are shown in bar graphs [(a,B), right panels]. Primary ALL cells were cocultured with normal bone marrow 
(NBM)- or ALL-MSC previously treated with CoCl2 or carbenoxolone to regulate CXCL12 expression. The culture system was pulsed with bromodeoxyuridine (BrdU), 
and its incorporation by leukemic cells was evaluated by flow cytometry (c) (NNBM = 4, NALL = 5).
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(47, 48). MSC are part of the complex tissue network of the 
BM microenvironment (42) that establishes an essential niche 
for hematopoiesis (49). Here, our data suggest that ALL-MSC 
are defective in their proliferation and CFU-F capabilities, in 
concordance to observations in myeloid leukemias (50). This 
behavior may relate to the apparent decreased levels of Sox9 
that regulates proliferation, survival, and chondrogenesis (51). 
Moreover, similar defects have been found in myelodysplastic 
syndrome patients (52, 53), in association to chromosomal 
abnormalities (54). Evaluating the existence of chromosomal 
alterations in ALL-MSC should be imperative, as it could com-
promise their biological functions. We have previously reported 
a critical decrease in the content of HSPC in BM from ALL 
patients and a concomitant impaired lymphoid differentiation 
potential (4). When the hematopoietic support is tested for 
ALL-MSC, B-cell differentiation is favored, suggesting that this 
stroma is providing the necessary signals to develop B cells. 
Although their origins—normal or leukemic—remain elusive, 
our short-term cocultures suggest a permissive role for leukemia 
precursor cells (data not shown).
One of the biological properties of MSC is their immune-
regulatory capability mediated by TLRs and cytokine receptors 
(55), suggesting a dual role: anti-inflammatory and pro-inflam-
matory. Typically, when MSC are exposed to pro-inflammatory 
cytokines, including IFNγ, TNFα, IL-1α, and IL-1β, they adopt 
an immune-suppressive phenotype to limit inflammation previ-
ous activation. ALL-MSC expressed high levels of activated 
NF-κB that may result from a number of mechanisms operating 
together, e.g., inflammation or a VCAM-1/VLA-4 axis activation 
signaling (56). Interestingly, NF-κB activation via TNFα on MSC 
stimulates its osteogenic differentiation (57), but we did not find 
an ostegenesis-bias behavior in this study. In contrast to normal 
MSC that inhibit NK cytotoxic activity, recent data have shown 
that ALL-MSC are capable of activating NK cells and that this 
FigUre 6 | remodeling of the lymphoid normal niche is associated with leukemic colonization concomitant to displacement of normal progenitors. 
Stromal spheroids were cocultured with acute lymphoblastic leukemia (ALL) primary cells (a). The colonization was confirmed by immunofluorescence microscopy 
after staining CD34+ cells with fluorescent dyes red and blue (B). Viability of leukemic cells harvested from 2D and tridimensional (3D) cocultures was assessed by 
flow cytometry after 7 days (c). CXCL12 was evaluated by flow cytometry in 3D MSC spheroids after enzymatic digestion compared with 2D monolayer cultures 
(D). CD34+ cells from mobilized peripheral blood and CD34+ ALL cells were cocultured in a competence ratio 1:1 for 24 h in normal bone marrow (NBM) and ALL 
mesenchymal stromal cells (MSC) spheroids (e) or during 120 h in NBM-MSC spheroids (F). Spheroids were washed, and CXCL12 expression (green) was 
evaluated (N
NBM-CD34
+ = 2, N
ALL-CD34
+ = 2, NNBM-MSC = 3, NALL-MSC = 4).
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profile can be adopted by NBM-MSC when they are exposed 
to leukemia cells (58), supporting the notion of local activating 
factors that promote a feedback loop between MSC and leukemic 
precursors.
Secretion and transcription of CXCL12 by MSC is regulated 
through gap-junctions mainly formed by connexins where 
Cx-43 and connexin-45 orchestrate cellular communication 
within BM (35). CXCL12-abundant reticular cells in the 
reticular niche, which express the highest levels of CXCL12, also 
express the highest levels of Cx-43 (35). Furthermore, although 
adherence properties are dependent on cell interconnections 
where CXCL12 functions as an indispensable anchor molecule 
(35), the regulation of its production in BM samples has been 
controversial (46, 59).
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Taking together, our data suggest that the final defect in the 
CXCL12 production is modulated at distinct levels in ALL, which 
may include FGF-2-dependent miR-31 high activity (60). We do 
not discard the participation of additional regulatory compo-
nents other than hypoxia-related HIF-1α, based on the partial 
reestablishment of CXCL12 in hypoxia-like conditions.
Other compensatory mechanisms could be operating through 
the vascular or endosteal niche in order to maintain residual 
normal hematopoiesis. Here, we confirmed that CXCL12 levels 
on MSC regulate the proliferation of leukemic cells using a 
coculture system with perturbed levels of CXCL12 by treatment 
with CoCl2 or by inhibition of Cx-43 (35). Our results suggest 
that CXCL12hi niche is acting like a leukemic repressor, contrary 
to a leukemic niche that favors proliferation by inhibiting the 
leukemic cell attachment to its stroma and promoting the 
entrance to cell cycle (61).
The lack of suitable in vitro conditions to maintain primary 
ALL cells plus the absence of phenotypic markers to distinguish 
normal and leukemic cells has delayed our disease understand-
ing. Currently, the number of reports about the benefits of using 
3D cultures is growing (62), and its use to increase the survival 
of leukemic cells may consummate important questions. Our 
observations support this notion by showing a better maintenance 
of primary ALL cells. Moreover, this novel model may allow the 
study of human–human and patient–patient microenvironment 
interactions and further contribute to precision medicine advance.
So far our findings concur with observations in animal models 
of changes in adhesion molecules and production of soluble fac-
tors controlled by malignant cells (24, 63, 64). Remarkably, the 
cellular communication between leukemic cells and MSC through 
exosomes or across nanotubes (65, 66) and the disruption of the 
CXCR4/CXCL12 axis (28, 59), suggesting a key role for G-CSF in 
this phenomena, are consistent with our previous reports about 
production of pro-inflammatory factors by tumor cells (30), 
related to G-CSF and Gfi-1 (29). Accordingly, G-CSF administra-
tion in a preclinical model of ALL showed an increased tumor 
burden (67), and its mechanism may be operating in the niche 
because B cell malignances rarely expressed G-CSF receptor and 
are unable to respond in vitro to this cytokine (68). In contrast, 
in vitro normal B-cell production in a stromal-free model is more 
efficient when G-CSF is supplied (69).
Loss of normal hematopoiesis is a classical event during human 
myeloproliferative neoplasias and leukemias where the niche 
downregulate essential HSPC retention factors as CXCL12, SCF, 
FigUre 7 | remodeling of B-lineage niche in acute lymphoblastic leukemia bone marrow: a model. Suitable hematopoietic niches that support B-cell 
lymphopoiesis are formed by mesenchymal stromal cells (MSC) capable of producing high amounts of CXCL12 and SCF (green MSC) that may function by limiting 
the proliferation of lymphoid progenitors (blue) in the absence of pro-inflammatory factors and within a normal hypoxic microenvironment. During leukemogenesis 
settings, emerging leukemic clones (pink) hijack normal niches and progressively induce their remodeling and compromise CXCL12 and SFC expression (gray MSC). 
In this new sanctuary, niche edition is presumably mediated by the activation of MSC due to the pro-inflammatory elements that alter the balance and allow leukemic 
proliferation that result in the incompatibility of normal hematopoiesis in a feedback loop manner.
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